Literature DB >> 2663521

Lich-Gregoir anti-reflux operation: a surgical experience and 5-20 years of follow-up in 149 ureters.

R Linn1, Y Ginesin, M Bolkier, D R Levin.   

Abstract

The surgical management of vesicoureteral reflux and the choice between the many good procedures available continue to be debated by urologists. The goal of each procedure is to achieve as normal a function of the urinary system as possible, to eliminate urinary tract infections, and thus to prevent further kidney damage. We present our experience in 149 antireflux repair operations with a technique first described by Lich and Gregoir in 1961. The follow-up in this study is 5-20 years, throughout which recurrent infections, reflux and other operative complications have carefully been considered. The success rate of this operation was 92.5%, with an additional 3.75% success in repair operations. Discussion and evaluation of other repair methods are reviewed but, in our opinion the Lich-Gregoir technique, because of its simplicity, should be the method of choice and should be used more by urologists.

Entities:  

Mesh:

Year:  1989        PMID: 2663521     DOI: 10.1159/000471569

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  4 in total

Review 1.  [Therapeutic options for primary vesicoureteral reflux: endoscopic vs open surgical approach].

Authors:  C Ziesel; S Frees; J W Thüroff; R Stein
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

2.  [Primary vesicoureteral reflux].

Authors:  R Stein; C Ziesel; P Rubenwolf; R Beetz
Journal:  Urologe A       Date:  2013-01       Impact factor: 0.639

3.  Surgical management of vesicoureteral reflux by modified Gil-Vernet method.

Authors:  J Kliment; I Fetisov; J Svitac
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

Review 4.  Surgical management of vesicoureteral reflux in pediatric patients.

Authors:  Axel Heidenreich; Enver Ozgur; Tanja Becker; Gerald Haupt
Journal:  World J Urol       Date:  2004-06-18       Impact factor: 4.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.